Thyroid Gland Disorder Treatment Market Report and Forecast 2025-2034

The thyroid gland disorder treatment market was valued at USD 2.18 Billion in 2024, driven by the growing investments in the treatment of thyroid disorders across 8 major markets. The market is anticipated to grow at a CAGR of 3.10% during the forecast period of 2025-2034 to achieve a value of USD 2.96 Billion by 2034. The rise in awareness around the condition, along with the focus on early diagnosis also contribute to the market growth.

Thyroid Gland Disorder Treatment Market Overview

Thyroid gland disorder treatment involves managing conditions such as hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. It includes medications like levothyroxine, antithyroid drugs, radioactive iodine therapy, and surgical interventions. The goal is to restore hormonal balance, alleviate symptoms, and prevent complications. The prevalence of hypothyroidism (HT) in the United States rose from 9.5% in 2012 to 11.7% in 2019, with over 78% of patients receiving thyroxine (T4) monotherapy. The NHANES dataset confirmed that T4 replacement therapy remains the most commonly used treatment for HT. During the same period, the proportion of patients with untreated HT increased from 11.8% to 14.4%. Treatment is tailored to the disorder type and patient’s condition, often requiring lifelong monitoring to ensure effective thyroid function and improved quality of life. The market is expected to grow at a CAGR of 3.10% during the forecast period of 2025-2034.

Thyroid Gland Disorder Treatment Market Growth Drivers

Regulatory Approvals Enhancing Market Growth

Rising demand for targeted, nonsurgical therapies and the growing focus on autoimmune thyroid-related conditions are transforming treatment protocols. For instance, in September  2024, Japan’s Ministry of Health approved a biologic therapy for active Thyroid Eye Disease (TED), marking the first such approval in Asia. The therapy offers a nonsurgical, nonsteroidal option to treat the root cause of TED. This development is expected to significantly improve access to advanced treatments across Asia, expanding the market in the forecast period through increased adoption and reduced dependence on invasive interventions.

Molecular Advancements to Drive Thyroid Gland Disorder Treatment Market Value

Precision oncology and pediatric inclusivity in thyroid cancer care are emerging as strong growth drivers in the market. For instance, in September  2024, the FDA granted full approval for selpercatinib, a targeted RET inhibitor, to treat advanced or metastatic RET-mutant medullary thyroid cancer in both adults and children aged two and older. The approval was based on robust Phase 3 trial results showing a 72% reduction in disease progression risk. This breakthrough is poised to drive substantial market growth by encouraging the adoption of molecular diagnostics and targeted therapies for thyroid malignancies in the upcoming years.

Thyroid Gland Disorder Treatment Market Trends

Some of the notable trends include an increase in collaborative initiatives between leading companies and academic institutions, growing preference for personalized treatments and adoption of digital health tools in the market.

Rising Disease Prevalence Elevates Market Value

The American Cancer Society projects  around 44,020 new thyroid cancer cases in the United States by 2025, predominantly affecting women and individuals in their early 50s. This growing incidence, especially among younger adults, underscores the increasing need for early diagnosis and effective treatments. As awareness rises and screening expands, the demand for thyroid gland disorder therapies is expected to grow significantly, driving market value in the forecast period.

Collaborative Awareness Initiatives to Drive Thyroid Gland Disorder Treatment Market Growth

In May  2023, during International Thyroid Awareness Week and World Thyroid Day, Merck partnered with Indonesian medical associations to launch the Thyroid RAISE program. This initiative aimed to enhance healthcare professionals’ skills and boost public awareness about thyroid disorder screening and diagnosis, particularly in high-risk adults and newborns. Such collaborative efforts are expected to improve early detection and treatment rates, accelerating market growth and development in thyroid gland disorder treatments.

Rising Demand for Personalized Therapies to Accelerate Thyroid Gland Disorder Treatment Market Growth

Increasing awareness of thyroid disorder heterogeneity is driving demand for personalized treatment approaches. Advances in genetic profiling and biomarker identification enable tailored therapies that improve patient outcomes. This trend is fostering innovation in drug development and enhancing treatment efficacy. As healthcare providers prioritize precision medicine, the market is expected to expand rapidly, with personalized therapies playing a critical role in future market growth.

Integration Of Digital Health Tools to Meet Rising Thyroid Gland Disorder Treatment Market Demand

The adoption of digital health technologies like remote monitoring and AI-powered diagnostics is transforming thyroid disorder management. These tools facilitate early diagnosis, continuous patient monitoring, and treatment optimization, improving adherence and outcomes. As healthcare systems increasingly incorporate digital solutions, the thyroid gland disorder treatment market benefits from enhanced patient engagement and streamlined care pathways, driving significant market development in the forecast period.

Thyroid Gland Disorder Treatment Market Segmentation

Thyroid Gland Disorder Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Hypothyroidism

Hyperthyroidism

Market Breakup by Treatment

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-Based Compounds
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Thyroid Gland Disorder Treatment Market Share

Hypothyroidism to Lead the Segmentation by Type

Hypothyroidism is expected to hold the largest market share due to its rising global prevalence, especially among women and the elderly. As per the analysis by Expert Market Research, the hypothyroidism market is expected to grow at a CAGR of 4.60% during the forecast period of 2025-2034.  With increasing awareness, improved diagnostics, and higher screening rates, more patients are being diagnosed early. The chronic nature of the condition demands lifelong hormone replacement therapy, driving consistent product demand. This segment’s strong therapeutic pipeline and high patient base position it as a key contributor to the thyroid gland disorder treatment market’s future expansion.

Levothyroxine to Hold a Significant Thyroid Gland Disorder Treatment Market Value for Segmentation by Treatment

Levothyroxine is anticipated to dominate the treatment segment as it remains the gold standard for managing hypothyroidism. Its long-standing clinical efficacy, affordability, and wide availability contribute to its continued preference among healthcare professionals. Rising diagnosis rates and long-term patient dependency support growing prescription volumes. Additionally, the drug’s inclusion in essential medicine lists globally strengthens its role in ensuring market growth during the forecast period.

Thyroid Gland Disorder Treatment Market Analysis by Region

A 2024 study conducted at the Outpatient Department of the National Institute of Unani Medicine in Bengaluru, India, reported a 7% prevalence of hypothyroidism in the study population, with 4% of cases self-reported and 3% previously undiagnosed. Additionally, 4% of participants were found to have subclinical hypothyroidism. These findings highlight the growing burden of thyroid disorders in India and support the country’s emerging role in the hypothyroidism treatment market.

The United States is expected to continue leading the market due to its high hypothyroidism prevalence, comprehensive screening programs, and strong access to specialized endocrine care. Japan maintains a significant share, supported by an aging population that is more susceptible to thyroid dysfunction. In Europe, countries like Germany and France benefit from universal healthcare systems that provide consistent coverage for chronic thyroid conditions.

Leading Players in the Thyroid Gland Disorder Treatment Market

The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

AbbVie Inc.

AbbVie Inc., headquartered in North Chicago, Illinois, was founded in 2013 after its separation from Abbott Laboratories. The company offers a diverse portfolio in specialty pharmaceuticals, including treatments for endocrine disorders. In the thyroid gland disorder treatment market, AbbVie is known for providing hormone therapies, particularly levothyroxine-based solutions, aimed at managing hypothyroidism and related conditions effectively.

Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology firm specializing in innovative therapies. While primarily focused on oncology and nephrology, Amgen supports thyroid gland disorder treatment through research and biological therapies that address hormone imbalances and autoimmune-related thyroid diseases, aligning with its broader endocrine and metabolic disorder solutions.

GSK Plc

GSK Plc, a British multinational headquartered in London and founded in 2000 through a merger, focuses on pharmaceuticals, vaccines, and consumer healthcare. In the thyroid gland disorder treatment market, GSK provides therapies that target autoimmune conditions like Graves’ disease and thyrotoxicosis. Its extensive R&D capabilities contribute to advancements in hormone regulation and thyroid-related metabolic treatment options.

Merck KGaA

Merck KGaA, based in Darmstadt, Germany, and founded in 1668, is a science and technology leader with a strong pharmaceutical portfolio. In the thyroid disorder treatment market, Merck offers levothyroxine-based medications and supports research on hormonal imbalances and thyroid cancer. Its legacy in endocrinology has made it a key player in addressing thyroid dysfunction globally.

Other key players in the market include Viatris Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Elexis Inc., and IBSA Pharma (IBSA Group).

Key Questions Answered in the Thyroid Gland Disorder Treatment Market

• What was the thyroid gland disorder treatment market value in 2024?
• What is the thyroid gland disorder treatment market forecast outlook for 2025-2034?
• What are the major factors aiding the thyroid gland disorder treatment market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major thyroid gland disorder treatment market trends?
• Which type will lead the market segment?
• Which treatment will lead the market segment?
• Which route of administration will lead the market segment?
• Which distribution channel will lead the market segment?
• Who are the key players involved in the thyroid gland disorder treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?